These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 14705265)

  • 1. The benefits and costs of tamoxifen for breast cancer prevention.
    Eckermann SD; Martin AJ; Stockler MR; Simes RJ
    Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
    Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
    Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective.
    Delea TE; El-Ouagari K; Karnon J; Sofrygin O
    Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
    Imai H; Kuroi K; Ohsumi S; Ono M; Shimozuma K
    Breast Cancer; 2007; 14(1):81-7. PubMed ID: 17245000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
    Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
    Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V
    Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
    van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
    Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.
    Karnon J; Delea T; Barghout V
    Eur J Health Econ; 2008 May; 9(2):171-83. PubMed ID: 17602251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer: a literature-based model analysis of costs in the Italian National Health Service.
    Marchetti M; Caruggi M; Colombo G
    Clin Ther; 2004 Sep; 26(9):1546-61. PubMed ID: 15531017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen for breast cancer prevention: a framework for clinical decisions.
    Cykert S; Phifer N; Hansen C
    Obstet Gynecol; 2004 Sep; 104(3):433-42. PubMed ID: 15339751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with hormone-responsive early breast cancer.
    Delea TE; Taneja C; Sofrygin O; Kaura S; Gnant M
    Clin Breast Cancer; 2010 Aug; 10(4):267-74. PubMed ID: 20705558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
    Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
    J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
    Smith TJ; Hillner BE
    J Clin Oncol; 2000 Jan; 18(2):284-6. PubMed ID: 10637241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of high adherence to tamoxifen in women with breast cancer: a community-based cohort study.
    McCowan C; Wang S; Thompson AM; Makubate B; Petrie DJ
    Br J Cancer; 2013 Sep; 109(5):1172-80. PubMed ID: 23949153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective.
    Karnon J; Delea T; Johnston SR; Smith R; Brandman J; Sung J; Goss PE
    Pharmacoeconomics; 2006; 24(3):237-50. PubMed ID: 16519546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of switching to exemestane versus continued tamoxifen as adjuvant therapy for postmenopausal women with primary breast cancer.
    Risebrough NA; Verma S; Trudeau M; Mittmann N
    Cancer; 2007 Aug; 110(3):499-508. PubMed ID: 17592825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line hormonal therapy: for advanced breast cancer in postmenopausal patients.
    Karnon J; Jones T
    Pharmacoeconomics; 2003; 21(7):513-25. PubMed ID: 12696991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.